Clinical Trials Logo

Stage I Bladder Cancer clinical trials

View clinical trials related to Stage I Bladder Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT02808143 Active, not recruiting - Clinical trials for Recurrent Bladder Carcinoma

Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

Start date: February 10, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the efficacy (the effect of drug on tumor) and the tolerability (the effect of drug on the body) of pembrolizumab, when given as a single agent in patients with bladder tumors. Another purpose of the study is to see what tumor characteristics are associated with increased efficacy of the pembrolizumab. Pembrolizumab (MK-3475) is an antibody (a human protein that sticks to a part of the tumor and/or immune cells) designed to allow the body's immune system to work against tumor cells. Pembrolizumab is Food and drug Administration (FDA) approved for the treatment of advanced melanoma (a type of skin cancer) and some types of lung cancer. It is not yet approved by the United States Food and Drug Administration (USFDA) for bladder cancer, hence it is considered an investigational agent for this disease.

NCT ID: NCT02252393 Withdrawn - Clinical trials for Recurrent Bladder Cancer

Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer

Start date: October 2015
Phase: N/A
Study type: Interventional

This randomized clinical trial studies intracorporeal or extracorporeal urinary diversion during robotic assisted radical cystectomy in reducing complications in patients with bladder cancer. Radical cystectomy is surgery to remove the entire bladder as well as nearby tissues and organs. After the bladder is removed, urinary diversion (a surgical procedure to make a new way for urine to leave the body) is performed. It is not yet known whether intracorporeal (within the body) or extracorporeal (outside of the body) urinary diversion is a better method in patients with bladder cancer undergoing robotic assisted radical cystectomy.

NCT ID: NCT01108003 Terminated - Clinical trials for Transitional Cell Carcinoma of the Bladder

Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery

Start date: April 2010
Phase: N/A
Study type: Interventional

Rationale: Broccoli sprout extract contains ingredients that may prevent or slow the growth of certain cancers. Purpose: This pilot study is studying the side effects of broccoli sprout extract in treating patients with transitional cell bladder cancer undergoing surgery.

NCT ID: NCT00666562 Completed - Clinical trials for Stage III Bladder Cancer

Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer

Start date: July 2, 2008
Phase: Phase 2
Study type: Interventional

Green tea extract contains ingredients that may slow the growth of certain cancers. It is not yet known whether green tea extract is more effective than a placebo when given before surgery in treating patients with bladder. This randomized phase II trial is studying green tea extract to see how well it works compared to a placebo when given before surgery in treating patients with nonmetastatic bladder cancer.

NCT ID: NCT00072137 Terminated - Clinical trials for Bladder Urothelial Carcinoma

Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy

Start date: October 2003
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of vaccine therapy given directly into the bladder in treating patients who are undergoing surgery to remove all or part of the bladder. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Giving a vaccine directly into the bladder before surgery may cause a stronger immune response and keep tumor cells from coming back after surgery.

NCT ID: NCT00003167 Completed - Clinical trials for Stage IV Bladder Cancer

Gene Therapy in Treating Patients With Advanced Bladder Cancer

Start date: May 1998
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of gene therapy in treating patients with advanced bladder cancer. Inserting the p53 gene into a person's bladder cancer cells may improve the body's ability to fight cancer